Monashee Investment Management LLC Takes $2.24 Million Position in Dyne Therapeutics, Inc. $DYN

Monashee Investment Management LLC purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 114,525 shares of the company’s stock, valued at approximately $2,240,000. Dyne Therapeutics accounts for about 1.3% of Monashee Investment Management LLC’s portfolio, making the stock its 26th largest position.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Strs Ohio acquired a new stake in shares of Dyne Therapeutics during the 4th quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dyne Therapeutics by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after acquiring an additional 1,440 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Dyne Therapeutics by 275.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Dyne Therapeutics by 1,006.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 10,499 shares of the company’s stock valued at $205,000 after acquiring an additional 9,550 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at approximately $147,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Dyne Therapeutics

In related news, Director Brian S. Posner acquired 2,000 shares of the stock in a transaction dated Monday, June 8th. The stock was bought at an average cost of $16.94 per share, with a total value of $33,880.00. Following the purchase, the director directly owned 24,500 shares of the company’s stock, valued at approximately $415,030. This represents a 8.89% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jason P. Rhodes sold 83,219 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the sale, the director directly owned 7,962 shares of the company’s stock, valued at $144,749.16. This represents a 91.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders bought 9,000 shares of company stock worth $156,800 and sold 1,559,462 shares worth $29,814,746. 9.46% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DYN has been the subject of a number of research reports. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a research report on Friday, May 15th. Sanford C. Bernstein lifted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Morgan Stanley reduced their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Finally, HC Wainwright cut their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Dyne Therapeutics Stock Up 1.6%

Shares of NASDAQ DYN opened at $17.95 on Friday. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00. The firm has a fifty day moving average of $18.27 and a 200-day moving average of $18.18. The stock has a market capitalization of $2.97 billion, a PE ratio of -5.57 and a beta of 1.09. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter in the previous year, the firm earned ($1.05) EPS. On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.